NO20052203D0 - Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin - Google Patents

Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin

Info

Publication number
NO20052203D0
NO20052203D0 NO20052203A NO20052203A NO20052203D0 NO 20052203 D0 NO20052203 D0 NO 20052203D0 NO 20052203 A NO20052203 A NO 20052203A NO 20052203 A NO20052203 A NO 20052203A NO 20052203 D0 NO20052203 D0 NO 20052203D0
Authority
NO
Norway
Prior art keywords
cytokine
bind
inhibit
activity
mutein
Prior art date
Application number
NO20052203A
Other languages
English (en)
Other versions
NO337024B1 (no
NO20052203L (no
Inventor
Charles Dinarello
Soo-Hyun Kim
Philip Bufler
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20052203D0 publication Critical patent/NO20052203D0/no
Publication of NO20052203L publication Critical patent/NO20052203L/no
Publication of NO337024B1 publication Critical patent/NO337024B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
NO20052203A 2002-10-08 2005-05-04 Anvendelse av cytokin-1 IL-1F7b som kan binde IL-18BP, for fremstilling av et medikament for behandling eller forebygging av inflammatoriske sykdommer, samt en vektor som koder for nevnte cytokin og anvendelse av nevnte vektor NO337024B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41682702P 2002-10-08 2002-10-08
PCT/US2003/031378 WO2004032837A2 (en) 2002-10-08 2003-10-03 The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine

Publications (3)

Publication Number Publication Date
NO20052203D0 true NO20052203D0 (no) 2005-05-04
NO20052203L NO20052203L (no) 2005-05-04
NO337024B1 NO337024B1 (no) 2016-01-04

Family

ID=32093906

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052203A NO337024B1 (no) 2002-10-08 2005-05-04 Anvendelse av cytokin-1 IL-1F7b som kan binde IL-18BP, for fremstilling av et medikament for behandling eller forebygging av inflammatoriske sykdommer, samt en vektor som koder for nevnte cytokin og anvendelse av nevnte vektor

Country Status (15)

Country Link
US (2) US7279155B2 (no)
EP (1) EP1572291B1 (no)
JP (1) JP4563813B2 (no)
KR (1) KR101015682B1 (no)
CN (1) CN1909926A (no)
AU (1) AU2003299919B2 (no)
BR (1) BR0315155A (no)
CA (1) CA2500577C (no)
EA (1) EA008667B1 (no)
ES (1) ES2416510T3 (no)
IL (1) IL167769A (no)
MX (1) MXPA05003869A (no)
NO (1) NO337024B1 (no)
UA (1) UA86750C2 (no)
WO (1) WO2004032837A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
ES2416510T3 (es) * 2002-10-08 2013-08-01 Ares Trading S.A. Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CA2590338A1 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
EP2160475A4 (en) * 2007-05-22 2011-02-09 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US11524985B2 (en) * 2017-03-20 2022-12-13 Bio-Techne Corporation IL-37 fusion protein and methods of making and using same
JP2020533301A (ja) * 2017-09-06 2020-11-19 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ インターロイキン−１８バリアントとその利用法
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
DE69116565T2 (de) * 1990-10-25 1996-08-01 Genentech Inc Verwendung gegen reaktive sauerstoffverbindungen schützender wirkstoffe
WO1992013095A1 (en) 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
US5945310A (en) * 1997-05-19 1999-08-31 Smithkline Beecham Corporation DNA encoding members of the IL-1 family, IL-1 delta
US7220717B2 (en) * 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2318482C (en) 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors
US6342371B1 (en) 1999-04-16 2002-01-29 Smithkline Beecham Corporation Interleukin-1 homologue, IL-1H4
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
WO2001040247A1 (en) 1999-12-01 2001-06-07 Smithkline Beecham Corporation Interleukin-1 homologue, mat il-1h4
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
ES2416510T3 (es) * 2002-10-08 2013-08-01 Ares Trading S.A. Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina

Also Published As

Publication number Publication date
US7820156B2 (en) 2010-10-26
EA200500617A1 (ru) 2006-08-25
EP1572291A2 (en) 2005-09-14
US7279155B2 (en) 2007-10-09
CA2500577C (en) 2013-12-17
EP1572291A4 (en) 2009-06-24
AU2003299919B2 (en) 2009-08-06
JP4563813B2 (ja) 2010-10-13
ES2416510T3 (es) 2013-08-01
EP1572291B1 (en) 2013-04-03
AU2003299919A1 (en) 2004-05-04
WO2004032837A3 (en) 2006-04-13
BR0315155A (pt) 2005-08-16
NO337024B1 (no) 2016-01-04
CN1909926A (zh) 2007-02-07
NO20052203L (no) 2005-05-04
EA008667B1 (ru) 2007-06-29
US20090074710A1 (en) 2009-03-19
IL167769A (en) 2013-10-31
JP2006516953A (ja) 2006-07-13
KR20050074470A (ko) 2005-07-18
US20040120923A1 (en) 2004-06-24
UA86750C2 (ru) 2009-05-25
MXPA05003869A (es) 2005-06-22
KR101015682B1 (ko) 2011-02-22
WO2004032837A2 (en) 2004-04-22
CA2500577A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
NO20052203D0 (no) Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin
NL301089I2 (nl) imlifidase
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
EA200600869A1 (ru) Антитела, связывающие рецептор интерлейкина-4
BRPI0313733A8 (pt) Uso da proteína n beta cinase
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
NO20070087L (no) Anti-IL-13 antistoffer, krystaller av anti-IL-13 antistoffer og komplekser omfattende dem
DK2230308T3 (da) Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
TW200709817A (en) Platform antibody compositions
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
SE9800836D0 (sv) New Compounds
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
CY1112673T1 (el) Φαινοξυ αιθερες αμινοξεων
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
ES2340842T3 (es) Anticuerpos anti-apc no neutralizantes.
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
ATE486078T1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE410415T1 (de) Neue verbindungen
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees